U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C44H69NO12.H2O
Molecular Weight 822.0334
Optical Activity ( - )
Defined Stereocenters 14 / 14
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TACROLIMUS

SMILES

O.[H][C@]1(CC[C@@H](O)[C@@H](C1)OC)\C=C(/C)[C@@]2([H])OC(=O)[C@]3([H])CCCCN3C(=O)C(=O)[C@]4(O)O[C@@]([H])([C@H](C[C@H]4C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC

InChI

InChIKey=NWJQLQGQZSIBAF-MLAUYUEBSA-N
InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C44H69NO12
Molecular Weight 804.0182
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 14 / 14
E/Z Centers 1
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tacrolimus, previously known as FK506, is the active ingredient in Prograf. Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription. Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action is not known. Experimental evidence suggests that tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition of T-lymphocyte activation (i.e., immunosuppression). Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants, kidney transplants, heart transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
PROGRAF

Approved Use

Prograf is a calcineurin-inhibitor immunosuppressant indicated for: Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF)

Launch Date

1994
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 ng/mL
0.2 mg/kg 1 times / day multiple, oral
dose: 0.2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TACROLIMUS unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
6.2 ng/mL
4 mg 1 times / day multiple, oral
dose: 4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TACROLIMUS unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
372 ng × h/mL
0.2 mg/kg 1 times / day multiple, oral
dose: 0.2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TACROLIMUS unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
74 ng × h/mL
4 mg 1 times / day multiple, oral
dose: 4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TACROLIMUS unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Disc. AE: Anemia, Edema lung...
AEs leading to
discontinuation/dose reduction:
Anemia
Edema lung
Allergic reaction
Abnormal liver function tests
Bilirubinemia
Lymphoma like reaction
Diarrhea
Intestinal obstruction
Sources: Page: p. 79
5.2 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5.2 mg, 1 times / day
Sources:
unhealthy, adult
n = 60
Health Status: unhealthy
Condition: kidney transplantation
Age Group: adult
Population Size: 60
Sources:
8 mg single, oral
Highest studied dose
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
0.1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg/kg, 2 times / day
Co-administed with::
Azathioprine
Sources:
unhealthy, adult
Other AEs: Infection...
0.02 mg/kg single, intravenous
Dose: 0.02 mg/kg
Route: intravenous
Route: single
Dose: 0.02 mg/kg
Sources:
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: Renal Impairment
Age Group: adult
Population Size: 12
Sources:
0.03 % 1 times / day multiple, topical
Dose: 0.03 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.03 %, 1 times / day
Sources:
unhealthy
n = 31
Health Status: unhealthy
Condition: non-segmental vitiligo
Population Size: 31
Sources:
AEs

AEs

AESignificanceDosePopulation
Abnormal liver function tests Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Allergic reaction Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Anemia Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Bilirubinemia Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Diarrhea Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Edema lung Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Intestinal obstruction Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Lymphoma like reaction Disc. AE
0.15 mg/kg 2 times / day steady, oral
Dose: 0.15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.15 mg/kg, 2 times / day
Sources: Page: p. 79
unhealthy, 1.9 years (range: 3-15 years)
n = 91
Health Status: unhealthy
Condition: Primary Liver Transplantation
Age Group: 1.9 years (range: 3-15 years)
Sex: M+F
Population Size: 91
Sources: Page: p. 79
Infection serious
0.1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg/kg, 2 times / day
Co-administed with::
Azathioprine
Sources:
unhealthy, adult
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
yes
yes
yes
yes (co-administration study)
Comment: Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism.
Page: -
yes
yes (pharmacogenomic study)
Comment: Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism.
Page: -
PubMed

PubMed

TitleDatePubMed
Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients.
1994
Sudden hearing loss associated with tacrolimus in a kidney-pancreas allograft recipient.
1999 Jul
Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages.
1999 Mar
Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.
1999 May
Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.
1999 May
Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient.
1999 Oct
Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB.
1999 Sep
Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus.
2000
Suppressive effects of cyclosporin A and FK-506 on superoxide generation in human polymorphonuclear leukocytes primed by tumor necrosis factor alpha.
2000 Dec
Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy.
2000 Feb
Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy.
2000 Mar
FK506 inhibition of histamine release and cytokine production by mast cells and basophils.
2000 Mar
Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.
2000 Oct 27
Delayed transient neurologic toxicity due to tacrolimus: CT and MRI.
2000 Sep
Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient.
2001 Dec 15
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
2001 Dec 27
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids).
2001 Jun
Patents

Sample Use Guides

Dosage in Adult Kidney, Liver, or Heart Transplant Patients: Adult kidney transplant patients (Oral Dosage: daily doses should be administered as two divided doses, every 12 hours): in combination with azathioprine: 0.2 mg/kg/day; in combination with MMF/IL-2 receptor antagonist: 0.1 mg/kg/day. Adult liver transplant patients: 0.10-0.15 mg/kg/day. Adult heart transplant patients: 0.075 mg/kg/day. Prograf (TACROLIMUS) injection should be used only as a continuous IV infusion and when the patient cannot tolerate oral administration of Prograf capsules. Prograf injection should be discontinued as soon as the patient can tolerate oral administration of Prograf capsules, usually within 2-3 days. In a patient receiving an IV infusion, the first dose of oral therapy should be given 8-12 hours after discontinuing the IV infusion. The recommended starting dose of Prograf injection is 0.03-0.05 mg/kg/day in kidney and liver transplant and 0.01 mg/kg/day in heart transplant given as a continuous IV infusion. Adult patients should receive doses at the lower end of the dosing range. Concomitant adrenal corticosteroid therapy is recommended early post-transplantation. Dosage in Pediatric Liver Transplant Patients: (Oral Dosage): Pediatric liver transplant patients 0.15-0.20 mg/kg/day (daily doses should be administered as two divided doses, every 12 hours)
Route of Administration: Other
Tacrolimus at concentration of 0.06 μmol/L could promote collagen induced platelet aggregation, inhibit thrombin induced platelet aggregation, have no effect on ristocetin and vWF induced platelet aggregation function. Tacrolimus at concentration of 120 μmol/L and 240 μmol/L could reduce the platelet mitochondrial membrane potential and induce the expression of apoptosis protein caspase-3. In vitro experimental results showed that high concentration of tacrolimus could lead to platelet apoptosis. But the current therapeutic dose of tacrolimus at 0.06 μmol/L (which is equivalent to 50 ng/ml blood concentration) could have different effects on platelet aggregation function according to different stimulating agents.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:46:51 GMT 2023
Edited
by admin
on Fri Dec 15 15:46:51 GMT 2023
Record UNII
WM0HAQ4WNM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TACROLIMUS
EMA EPAR   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
FK 506
Code English
TACROLIMUS [ORANGE BOOK]
Common Name English
TACROLIMUS [USP-RS]
Common Name English
TACROLIMUS HYDRATE [JAN]
Common Name English
NSC-758659
Code English
MODIGRAF
Brand Name English
TACROLIMUS MONOHYDRATE
MI   WHO-DD  
Common Name English
TACROLIMUS [EMA EPAR]
Common Name English
PROTOPIC
Brand Name English
FK-506
Code English
FK506
Code English
TACROLIMUS HYDRATE
JAN  
Common Name English
TACROLIMUS [VANDF]
Common Name English
TACROLIMUS MONOHYDRATE [MI]
Common Name English
TACROLIMUS [USAN]
Common Name English
PROGRAF
Brand Name English
ADVAGRAF
Brand Name English
Tacrolimus monohydrate [WHO-DD]
Common Name English
15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-t
Systematic Name English
TACROLIMUS MONOHYDRATE [EP MONOGRAPH]
Common Name English
ENVARSUS XR
Brand Name English
(−)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-8-Allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3
Systematic Name English
FR-900506
Code English
FR900506
Code English
TACROLIMUS [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 472815
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 743220
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 534516
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
WHO-VATC QD11AH01
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 407113
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EMA ASSESSMENT REPORTS ADVAGRAF (AUTHORIZED: GRAFT REJECTION)
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 314310
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
LIVERTOX NBK548545
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
WHO-ATC L04AD02
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
NCI_THESAURUS C2201
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EMA ASSESSMENT REPORTS ENVARSUS (AUTHORIZED: GRAFT REJECTION)
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EMA ASSESSMENT REPORTS MODIGRAF (AUTHORIZED: GRAFT REJECTION)
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 468214
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 849321
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
NDF-RT N0000175457
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 701319
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 753620
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 203305
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EU-Orphan Drug EU/3/03/185
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
WHO-ATC D11AH01
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EMA ASSESSMENT REPORTS PROTOPIC (AUTHORIZED: PSORIASIS)
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
FDA ORPHAN DRUG 111398
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
NCI_THESAURUS C146638
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
WHO-VATC QL04AD02
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
EMA ASSESSMENT REPORTS PROTOPY (AUTHORIZED: DERMATATIS, ATOPIC)
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
Code System Code Type Description
NSC
758659
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL269732
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
EVMPD
SUB23141
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
NCI_THESAURUS
C1311
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
DRUG CENTRAL
2552
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
RXCUI
484288
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
CHEBI
61049
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
WIKIPEDIA
TACROLIMUS
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
CAS
109581-93-3
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
IUPHAR
6784
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
PUBCHEM
5282315
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
RXCUI
42316
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
ALTERNATIVE
SMS_ID
100000087996
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
EVMPD
SUB25193
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
DRUG BANK
DB00864
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
MESH
D016559
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
DAILYMED
WM0HAQ4WNM
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
LACTMED
Tacrolimus
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
MERCK INDEX
m10425
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY Merck Index
FDA UNII
WM0HAQ4WNM
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
CHEBI
61057
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
RS_ITEM_NUM
1642802
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
USAN
EE-43
Created by admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
MINOR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY